Stock Update (NYSE:PFE): Pfizer Reports Top-line Results from Postherpetic Neuralgia and Painful Diabetic Peripheral Neuropathy Lyrica® Studies Conducted in China

[at noodls] – NEW YORK–(BUSINESS WIRE)–Pfizer Inc. (NYSE:PFE) announced today top-line results from two placebo-controlled studies conducted in China with Lyrica® (pregabalin) in patients with postherpetic neuralgia … Read more on this. . . . → Read More: Stock Update (NYSE:PFE): Pfizer Reports Top-line Results from Postherpetic Neuralgia and Painful Diabetic Peripheral Neuropathy Lyrica® Studies Conducted in China Similar Articles: Market Update (NYSE:PFE): Pfizer Enters Into Agreement to Acquire Baxter’s Portfolio of Marketed Vaccines Market Update: Pfizer Inc (NYSE:PFE) – Pfizer Announces Submission of Biologics License Application to the FDA for Investigational Meningococcal B Vaccine Stock Update: Pfizer Inc (NYSE:PFE) – Pfizer lung cancer drug fails in two large studies